New England Surgical Society (NESS)
Search NESS
  Annual Meeting
  Annual Resident and Fellow Research Day
      Member Directory
      Members Only
  Scholars Foundation
  Job Board
  Journal of the American College of Surgeons
      Past Presidential Addresses
  Contact NESS


New Treatments for ER+ Breast Cancer

Sharon B Chang, Penelope Miron, Andrew L. Kung, Alexander Miron, James D. Iglehart
Dana-Farber Cancer Institute, Boston, MA

Estrogen receptor positive (ER+) breast cancers are treated by drugs that exploit their hormone dependence. These drugs include aromatase inhibitors and anti-estrogens like tamoxifen, but development of resistance can limit their use. Rapamycin, a bacterial product, may become an important adjunct to treatment; it inhibits the mammalian Target of Rapamycin (mTOR), which controls cell growth/proliferation. Furthermore, rapamycin is highly effective against ER+ breast cancer cell lines. We investigated the role of rapamycin/mTOR inhibition in E2-driven proliferation and E2-stimulated signal transduction.
Proliferation assays; Western and Northern blot analyses of MCF-7 breast cancer cells.
Cancer institute.
Treatment with rapamycin, 4-hydroxytamoxifen (4-OHT), and mTOR RNA interference (RNAi).
Main Outcome Measures:
Proliferation--MTS assay; phosphorylation of mTOR substrate S6K1; expression of E2-responsive gene pS2 transcript.
Rapamycin inhibited E2-driven proliferation of MCF-7 cells, and combinations of rapamycin and 4-OHT had additive inhibitory effects. Treatment of MCF-7 cells with E2 increased phosphorylation of S6K1 within 15 minutes; this phosphorylation was inhibited by rapamycin pretreatment and by mTOR RNAi. Rapamycin also inhibited induction of pS2 transcript by E2.
Rapamycin, alone and in combination with 4-OHT, potently inhibits E2 dependent proliferation of MCF-7 cells. mTOR appears to play a role in both early and later E2-stimulated signal transduction. These results suggest that inhibitors of mTOR such as rapamycin may be a powerful addition to the treatment of ER+ breast cancers.

Back to Final Program


Copyright © 2020 New England Surgical Society. All Rights Reserved.
Read Privacy Policy.